Skip to main content

Chronic Kidney Disease, Diabetes Mellitus, Hypertension and Medication Possession Ratio for ACEI/ARB Therapy

CBE ID
0550
Project
Renal Consensus Standards Endorsement Maintenance
Endorsed
New or Maintenance
Maintenance
Endorsement and Maintenance (E&M) Cycle
Full Year 2011
Is Under Review
No
Measure Description

Medication Possession Ratio (MPR) for ACEI/ARB therapy for individuals with Chronic Kidney Disease (CKD) and/or diabetes mellitus and hypertension.

  • Measure Type
    Process
    Electronic Clinical Quality Measure (eCQM)
    No
    Level Of Analysis
    Clinicians: Group
    Clinicians: Individual
    Other
    Care Setting
    Ambulatory Care: Clinic
    Other Care Setting (Please specify)
    Numerator

    The sum of the days supply that fall within the measurement window for an ACEI/ARB fill for each patient in the denominator.

    Time window: Anytime during the measurement period (12 months)

    MPR Numerator:
    1. New users: For patients with no prescriptions in the 180 days prior to the measurement period, sum of:

    Days’ supply of all medications from the first prescription until the end of the measurement period.

    **Remove the days’ supply that extend past the end of the measurement period.

    2. Continuous users: For patients with 1 or more prescriptions in the 180 days prior to the measurement period, sum of:

    Days’ supply of all medications in the measurement period

    **Remove the days supply that extends past the end of the measurement period and add days supply from the previous period that apply to the current period.

    Denominator

    Beneficiaries with CKD stages 1-4 and/or diabetes mellitus and hypertension (HTN) identified during the measurement period with at least one Part D claim for an ACEI/ARB.

    Time window: Anytime during the measurement period (12 consecutive months)

    MPR Denominator:
    1. New users: Number of days from the first prescription to the end of measurement period.
    2. Continuous users: Number of days from the beginning to the end of the measurement period

    Exclusions

    Patients who died during the measurement period.
    Patients who are actively enrolled in multiple plans concurrently as of the end of the measurement period.
    Patients who have had a kidney transplant during the measurement period.
    Patients who have ESRD.
    Patients with a diagnosis of polycystic ovaries who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.
    Patients with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.

    Testing Data Sources
    Electronic administrative data/claims
    Pharmacy data
  • Most Recent Endorsement Activity
    Measure Retired and Endorsement Removed Renal Consensus Standards Endorsement Maintenance 2011
    Initial Endorsement
    Endorsement Status
    Endorsement Removed
    Last Updated
    Removal Date